Cellico

South Korean medical-device startup (founded 2019; Pangyo/Seongnam, Gyeonggi) developing AR smart glasses for low vision (EyeCane) and an implantable artificial retina (“electronic eye”). Assignee of US11520154B2 (AR-glasses + intraocular-implant system) catalogued in visual-prosthesis-patents.

Company

  • Founded 2019 (celebrating its fourth year as of late 2023); CEO Kim Jungsuk; based in the Pangyo Techno Valley (Seongnam); ~30 IP rights reported by 2023; listed as Samsung-accelerated in trade-show profiles; “social venture” positioning — microelectronic eye devices and vision-correction smart glasses for visually impaired patients.

Products & milestones

  • EyeCane — AR glasses for low vision (AMD, glaucoma, diabetic retinopathy, retinal pigment degeneration, night blindness): a high-resolution camera plus real-time image processing that “replays” occluded areas of the field into the patient’s remaining peripheral vision (face recognition, reading, object finding); includes a big-data visual-field-test program for monitoring scotomas. Won CES Innovation Awards 2024 in three categories (Wearable Technologies, Digital Health, Accessibility & Aging Tech) after a CES 2023 award; Edison Awards in Health/Medical & Biotech (2023, 2024) and a 2025 finalist listing; developed in part with KBioHealth under a Korean MOTIE-supported project (2023–2025). Production and overseas launch were targeted for H1 2024 (company statements).
  • Implantable artificial retina — the family behind US11520154B2: a sunglasses-form external unit (camera → image processing → lens microdisplay) that optically drives an intraocular stimulation implant, moving image processing out of the eye (KR/US/CN/EP family, all active; US granted 2022).

Caveats

  • Company, funding and product status per Korean trade press and company statements; no peer-reviewed clinical validation captured; production timeline is a company target; confidence: medium.

References